Alterity Therapeutics Limited
ATHEAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | maintain | Buy | Jan 30, 2025 |
| Benchmark | maintain | Speculative Buy | Mar 7, 2024 |
| Ladenburg Thalmann | maintain | Buy | Jun 5, 2023 |
| Ladenburg Thalmann | maintain | Buy | Aug 3, 2022 |
| Goldman Sachs | maintain | Neutral | Jun 23, 2022 |
| Benchmark | maintain | Speculative Buy →Buy | Aug 20, 2021 |
| B. Riley FBR | maintain | Buy | Jan 5, 2018 |
| MLV & Co. | downgrade | Buy →Hold | Mar 31, 2014 |
| H.C. Wainwright | downgrade | Buy →Neutral | Mar 31, 2014 |
| H.C. Wainwright | maintain | Buy | Feb 26, 2014 |
| H.C. Wainwright | maintain | Buy | Feb 18, 2014 |
| Burrill & Company | maintain | Market Perform →Perform | Dec 20, 2012 |
Earnings History
Next report: Mar 4, 2027 · EPS est. $-0.03| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 28, 2026 | $-0.05 | $-0.11 | $806.6K | $2.3M |
| Feb 25, 2026 | $-0.42 | $-0.25 | $645.9K | $1.1M |
| Aug 28, 2025 | $-0.34 | $-0.56 | $4.1M | $5.1M |
| Feb 28, 2025 | $-0.57 | $-0.69 | $69.2K | $2.3M |
| Feb 3, 2025 | $-0.00 | — | $803.0K | — |
| Aug 29, 2024 | $-0.80 | $-0.07 | $1.4M | $910.1K |
| Apr 11, 2024 | $-0.00 | — | $1.1M | — |
| Feb 28, 2024 | $-1.10 | $-0.14 | $77.1K | $958.3K |
News
Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted for ATH434, extending protection to 2045 and supporting future development in Parkinson's disease Peer-reviewed publication in Clinical Autonomic Research from the bioMUSE Natural History Study linked skin α-synuclein deposition to autonomic dysfunction in early MSA Phase 3 operational activities unde…
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia.
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –